Furthermore, our in vivo data confirmed that overexpression of wild-type but not inactive mutant BAP1 significantly inhibited, while knockdown of BAP1 promoted, ICC tumorigenicity, and progression. This evidence concerns the gene BAP1 and intrahepatic cholangiocarcinoma.